Bufexamac

Source: Wikipedia, the free encyclopedia.
Bufexamac
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Topical, rectal
ATC code
Legal status
Legal status
Pharmacokinetic data
ExcretionRenal
Identifiers
  • 2-(4-butoxyphenyl)-N-hydroxyacetamide
JSmol)
  • ONC(=O)Cc1ccc(OCCCC)cc1
  • InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
  • Key:MXJWRABVEGLYDG-UHFFFAOYSA-N

Bufexamac is a drug used as an

rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe and Australia[1]
because of allergic reactions.

Indications

Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic

haemorrhoids.[2]

Pharmacology

Bufexamac is thought to act by inhibiting the enzyme

non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.[3]
Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10).[4]

Side effects

Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.[5] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.[6]

References

  1. ^ "Bufexamac Safety advisory - risk of serious skin reactions". Therapeutic Goods Administration (TGA). 2020.
  2. ISBN 978-3-7741-9846-3
    .
  3. ISBN 978-3-540-67174-9
    .
  4. S2CID 205275159
    .
  5. ^ "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt (in German) (47). 2000.
  6. ^ "European Medicines Agency recommends revocation of marketing authorisations for bufexamac" (PDF). European Medicines Agency. 2010-04-22. Archived from the original (PDF) on 2010-05-31. Retrieved 2010-05-01.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bufexamac&oldid=1170948050"